A Phase 3 interventional study of Sodium Bicarbonate (NaHCO3) and Warmed lignocaine in Dermatochalasis of Upper Eyelid and Blepharoplasty, sponsored by Prince of Wales Hospital, Shatin, Hong Kong. Not yet recruiting at 3 sites in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Prince of Wales Hospital, Shatin, Hong Kong · Phase 3, Interventional, and Treatment
The goal of this clinical trial is to determine whether buffering, warming, or addition of hyaluronidase or tranexamic acid to lignocaine during eyelid injection of local anaesthesia reduce injection pain and procedure-related pain and improve perioperative haemostasis.
The aim of the project is to test the hypothesis that the following modifications during subcutaneous eyelid injection of local anaesthesia, compared to 2% lignocaine with 1:200,000 adrenaline, reduce injection pain and procedure-related pain and improve perioperative haemostasis.
Exclusion Criteria:
One eyelid: lignocaine buffered with sodium bicarbonate; the other eyelid: unmodified solution of lignocaine
Drug: Sodium Bicarbonate (NaHCO3) · Drug: Lignocaine 2% concentration solution
One eyelid: lignocaine warmed to body temperature; the other eyelid: unmodified solution of lignocaine at room temperature
Drug: Warmed lignocaine · Drug: Lignocaine 2% concentration solution
One eyelid: lignocaine with hyaluronidase added; the other eyelid: unmodified solution of lignocaine
Drug: Hyaluronidase Injection · Drug: Lignocaine 2% concentration solution
One eyelid: lignocaine with tranexamic acid added; the other eyelid: unmodified solution of lignocaine
Drug: Tranexamic Acid (TXA) · Drug: Lignocaine 2% concentration solution
One eyelid: modification A; the other eyelid: modification B
Drug: Sodium Bicarbonate (NaHCO3) · Drug: Warmed lignocaine · Drug: Hyaluronidase Injection · Drug: Tranexamic Acid (TXA) · Drug: Lignocaine 2% concentration solution
One eyelid: modification A+B; the other eyelid: modification A
Drug: Sodium Bicarbonate (NaHCO3) · Drug: Warmed lignocaine · Drug: Hyaluronidase Injection · Drug: Tranexamic Acid (TXA) · Drug: Lignocaine 2% concentration solution
One eyelid: modification A+B; the other eyelid: modification B
Drug: Sodium Bicarbonate (NaHCO3) · Drug: Warmed lignocaine · Drug: Hyaluronidase Injection · Drug: Tranexamic Acid (TXA) · Drug: Lignocaine 2% concentration solution
Lignocaine buffered with sodium bicarbonate
Lignocaine warmed to body temperature
Lignocaine with hyaluronidase added
Lignocaine with tranexamic acid added
2% lignocaine with 1:200,000 adrenaline
Pain of injection of local anaesthesia
Pain of injection of local anaesthesia, measured by a pain rating visual analogue scale of minimum 0 to maximum 10 (10 refers to worst pain)
Time frame: Within 1 minute after injection of local anaesthesia
Pain encountered during the surgery
Pain encountered during the surgery, measured by a pain rating visual analogue scale of minimum 0 to maximum 10 (10 refers to worst pain)
Time frame: Within 15 minutes after surgery
Pain encountered one week after surgery
Pain encountered one week after surgery, measured by a pain rating visual analogue scale of minimum 0 to maximum 10 (10 refers to worst pain)
Time frame: One week after surgery
Postoperative ecchymosis at one week after surgery
Postoperative ecchymosis at one week after surgery, rated based on clinical photos using a standardised rating score of minimum 0 to maximum 5 (5 refers to worst ecchymosis)
Time frame: One week after surgery
Postoperative swelling at one week after surgery
Postoperative swelling at one week after surgery, rated based on clinical photos using a standardised rating score of minimum 0 to maximum 5 (5 refers to worst swelling)
Time frame: One week after surgery
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — The datasets used and/or analysed during the current study are available from the principal investigator on reasonable request.
Supporting information: Study protocol, Sap, Icf, Csr, Analytic code
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prince of Wales Hospital, Shatin, Hong Kong